Wockhardt Limited, is a research based global pharmaceutical and biotech major, has reported Q1 FY25 revenue growth of 14% to register Rs. 747 crore compared to Rs. 658 crore in the previous year. 

The company has registered YoY growth of 216% in EBITDA in Q1 FY25. EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year. 

UK Business stood at Rs. 276 crore in Q1 FY25 compared to Rs. 247 crore in Q1 FY24 registering a growth of 12% and contributed about 37% of global revenue in the current quarter. Emerging Markets Business of the company stood at Rs. 191 crore in Q1 FY25 registering a growth of 44% and contributing to about 26% of the global revenue. 

Irish Business stood at Rs. 45 crore in Q1 FY25 with a flat growth compared to the previous year. India Branded Business stood at Rs. 123 crore in Q1 FY25 compared to Rs. 100 crore in the previous year registering a growth of 23% and contributing to 16% of the global revenue. US Business stood at Rs. 30 crore in Q1 FY25 contributing 4% of the global revenue. 

Novel Antibiotic Update:

ZAYNICH: We continue to recruit more patients for our global clinical trial and have recruited 422 patients. Clinical trial study progressing in 9 countries. We have completed 33 patients for compassionate use after approval of usage by DCGI. The product resulted in 100% cure and was found to be safe even when administered upto 60 days. 

Meropenem Resistance Clinical Trial: DCGI has advised to do a clinical trial of 60 patients. 25% of patients have been recruited. This clinical trial would be completed within the next 8 to 9 months after which WCK 5222 (ZAYNICH) can be launched in India by early 2025. 

MIQNAF: The company has announced the completion of the pivotal Phase 3 pneumonia study of its antibiotic Nafithromycin WCK 4873 (MIQNAF). The product has been filed for DCGI approval which is expected in the Q3 FY25. Commercial launch expected in Q4 FY25. 

Wockhardt is a research based global pharmaceutical and biotech company. Wockhardt’s New Drug Discovery programme has focussed on the unmet need of antibacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for six of our antibacterial discovery programmes – three of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”. It has a comprehensive drug discovery team and clinical organisation. 

Wockhardt is employing around 2,600 people and 27 nationalities with presence in the USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in the USA, Europe, and India, with 78% of its global revenues coming from international businesses.